Skip to main content

Advertisement

SpringerLink
Log in

von Willebrand factor: at the crossroads of bleeding and thrombosis

  • Progress in Hematology
  • Current understanding of thrombosis and hemostasis—from bench to bedside
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Hemostasis and thrombosis represent two sides of the same coin. Hemostasis maintains blood fluidity in the vascular system while allowing for rapid thrombus formation to prevent excessive hemorrhage after blood vessel injury. Thrombosis is a pathologic extension of the normal hemostatic mechanism, occurring when unwanted clot formation develops in certain pathological situations. The molecular mechanisms underlying both phenomena are fundamentally identical. One of the key players in both processes is the plasma glycoprotein von Willebrand factor, which perfectly illustrates this duality between hemostatic and thrombotic mechanisms. The purpose of this review is to discuss novel findings on the role of von Willebrand factor at this interface, and how some of these findings may help develop new therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(Suppl 5):11–26.

    Article  PubMed  CAS  Google Scholar 

  2. Ruggeri ZM. Platelet adhesion under flow. Microcirculation. 2009;16:58–83.

    Article  PubMed  CAS  Google Scholar 

  3. Lenting PJ, Van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5:1353–60.

    Article  PubMed  CAS  Google Scholar 

  4. Denis CV. Molecular and cellular biology of von Willebrand factor. Int J Hematol. 2002;75:3–8.

    Article  PubMed  CAS  Google Scholar 

  5. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57:1140–3.

    PubMed  CAS  Google Scholar 

  6. Furlan M. von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72:341–8.

    Article  PubMed  CAS  Google Scholar 

  7. Barr J, Motto D. Modulation of von Willebrand factor by ADAMTS13. In: Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR, editors. Von Willebrand disease: basic and clinical aspects. Chichester: Wiley-Blackwell; 2011. p. 49–62.

    Chapter  Google Scholar 

  8. Springer TA. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost. 2011;9(Suppl 1):130–43.

    Article  PubMed  CAS  Google Scholar 

  9. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103–14.

    Article  PubMed  CAS  Google Scholar 

  10. Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol. 2005;42:15–28.

    Article  PubMed  CAS  Google Scholar 

  11. Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost. 2011;9(Suppl 1):209–15.

    Article  PubMed  CAS  Google Scholar 

  12. Rayes J, Hommais A, Legendre P, Tout H, Veyradier A, Obert B, et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost. 2007;5:321–8.

    Article  PubMed  CAS  Google Scholar 

  13. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113:526–34.

    Article  PubMed  CAS  Google Scholar 

  14. Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, Christophe OD, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood. 2010;115:4870–7.

    Article  PubMed  CAS  Google Scholar 

  15. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74:1591–9.

    PubMed  CAS  Google Scholar 

  16. Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8:1431–3.

    Article  PubMed  CAS  Google Scholar 

  17. Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost. 2001;86:848–54.

    PubMed  CAS  Google Scholar 

  18. Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood. 2009;114:3489–96.

    Article  PubMed  CAS  Google Scholar 

  19. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, Verbeuren TJ, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008;112:603–9.

    Article  PubMed  CAS  Google Scholar 

  20. Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99:180–4.

    Article  PubMed  CAS  Google Scholar 

  21. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279:12102–9.

    Article  PubMed  CAS  Google Scholar 

  22. Pruss CM, Golder M, Bryant A, Hegadorn CA, Burnett E, Laverty K, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 2011;117:4358–66.

    Article  PubMed  CAS  Google Scholar 

  23. Denis CV, Christophe OD, Oortwijn BD, Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost. 2008;99:271–8.

    PubMed  CAS  Google Scholar 

  24. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111:4979–85.

    Article  PubMed  CAS  Google Scholar 

  25. Van Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3:2228–37.

    Article  PubMed  CAS  Google Scholar 

  26. Federici AB, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011;37:511–21.

    Article  PubMed  CAS  Google Scholar 

  27. Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011;105:647–54.

    Article  PubMed  CAS  Google Scholar 

  28. Shetty S, Kasatkar P, Ghosh K. Pathophysiology of acquired von Willebrand disease: a concise review. Eur J Haematol. 2011;87:99–106.

    Article  PubMed  CAS  Google Scholar 

  29. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117:6777–85.

    Article  PubMed  CAS  Google Scholar 

  30. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 1993;82:1749–57.

    PubMed  CAS  Google Scholar 

  31. Richard C, Cuadrado MA, Prieto M, Batlle J, Lopez Fernandez MF, Rodriguez Salazar ML, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol. 1990;35:114–7.

    Article  PubMed  CAS  Google Scholar 

  32. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood. 1986;67:758–61.

    PubMed  CAS  Google Scholar 

  33. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340:35–7.

    Article  PubMed  CAS  Google Scholar 

  34. Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–9.

    Article  PubMed  Google Scholar 

  35. Banerjee AK. Angiodysplasia associated with hypertrophic obstructive cardiomyopathy (HOCM). Br J Clin Pract. 1990;44:326–7.

    PubMed  CAS  Google Scholar 

  36. Le Tourneau T, Susen S, Caron C, Millaire A, Marechaux S, Polge AS, et al. Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation. 2008;118:1550–7.

    Article  PubMed  Google Scholar 

  37. Slaughter MS. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res. 2010;3:618–24.

    Article  PubMed  Google Scholar 

  38. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation. 2000;102:1290–5.

    PubMed  CAS  Google Scholar 

  39. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009;324:1330–4.

    Article  PubMed  CAS  Google Scholar 

  40. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9:899–908.

    Article  PubMed  Google Scholar 

  41. De Meyer SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord: Drug Targets. 2009;9:9–20.

    Article  Google Scholar 

  42. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:3071–8.

    Article  PubMed  CAS  Google Scholar 

  43. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol. 2000;20:2019–23.

    Article  PubMed  CAS  Google Scholar 

  44. Klemm T, Mehnert AK, Siegemund A, Wiesner TD, Gelbrich G, Bluher M, et al. Impact of the Thr789Ala variant of the von Willebrand factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2005;113:568–72.

    Article  PubMed  CAS  Google Scholar 

  45. Lacquemant C, Gaucher C, Delorme C, Chatellier G, Gallois Y, Rodier M, et al. Association between high von willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group. Kidney Int. 2000;57:1437–43.

    Article  PubMed  CAS  Google Scholar 

  46. van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol. 2004;124:343–7.

    Article  PubMed  Google Scholar 

  47. Smith NL, Rice KM, Bovill EG, Cushman M, Bis JC, McKnight B, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood. 2011;117:6007–11.

    Article  PubMed  CAS  Google Scholar 

  48. Antoni G, Oudot-Mellakh T, Dimitromanolakis A, Germain M, Cohen W, Wells P, et al. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet. 2011;12:102.

    Article  PubMed  CAS  Google Scholar 

  49. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121:1382–92.

    Article  PubMed  CAS  Google Scholar 

  50. van Loon JE, Leebeek FW, Deckers JW, Dippel DW, Poldermans D, Strachan DP, et al. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet. 2010;3:507–12.

    Article  PubMed  Google Scholar 

  51. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–5.

    Article  PubMed  CAS  Google Scholar 

  52. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636–42.

    Article  PubMed  Google Scholar 

  53. Takahashi M, Yamashita A, Moriguchi-Goto S, Marutsuka K, Sato Y, Yamamoto H, et al. Critical role of von Willebrand factor and platelet interaction in venous thromboembolism. Histol Histopathol. 2009;24:1391–8.

    PubMed  CAS  Google Scholar 

  54. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109:2424–9.

    Article  PubMed  CAS  Google Scholar 

  55. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400–7.

    Article  PubMed  CAS  Google Scholar 

  56. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880–5.

    Article  PubMed  CAS  Google Scholar 

  57. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011;118:3708–14.

    Article  PubMed  CAS  Google Scholar 

  58. Brill A, Fuchs TA, Savchenko A, Thomas GM, Martinod K, De Meyer SF, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2011 (Epub ahead of print).

  59. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432–5.

    Article  PubMed  CAS  Google Scholar 

  60. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106:11–7.

    Article  PubMed  CAS  Google Scholar 

  61. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118:3212–21.

    Article  PubMed  CAS  Google Scholar 

  62. Lenting PJ, Pegon JN, Groot E, de Groot PG. Regulation of von Willebrand factor–platelet interactions. Thromb Haemost. 2010;104:449–55.

    Article  PubMed  CAS  Google Scholar 

  63. De Ceunynck K, Rocha S, Feys HB, De Meyer SF, Uji-i H, Deckmyn H, et al. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem. 2011;286:36361–7.

    Article  PubMed  Google Scholar 

  64. Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A. 2007;104:7899–903.

    Article  PubMed  CAS  Google Scholar 

  65. Lenting PJ, Rastegarlari G. ADAMTS-13: double trouble for von Willebrand factor. J Thromb Haemost. 2010;8:2775–7.

    Article  PubMed  CAS  Google Scholar 

  66. Ganderton T, Berndt MC, Chesterman CN, Hogg PJ. Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost. 2007;5:204–6.

    Article  PubMed  CAS  Google Scholar 

  67. Li Y, Choi H, Zhou Z, Nolasco L, Pownall HJ, Voorberg J, et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost. 2008;6:1135–43.

    Article  PubMed  CAS  Google Scholar 

  68. Yeh HC, Zhou Z, Choi H, Tekeoglu S, May W 3rd, Wang C, et al. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost. 2010;8:2778–88.

    Article  PubMed  CAS  Google Scholar 

  69. Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, Lopez JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood. 2011;118:5283–91.

    Article  PubMed  CAS  Google Scholar 

  70. Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115:706–12.

    Article  PubMed  CAS  Google Scholar 

  71. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, et al. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 2010;48:446–56.

    Article  PubMed  CAS  Google Scholar 

  72. De Filippis V, Lancellotti S, Maset F, Spolaore B, Pozzi N, Gambaro G, et al. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J. 2011 (Epub ahead of print).

  73. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106:3035–42.

    Article  PubMed  CAS  Google Scholar 

  74. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood. 2007;110:1483–91.

    Article  PubMed  CAS  Google Scholar 

  75. de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, et al. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood. 2009;114:3656–61.

    Article  PubMed  Google Scholar 

  76. De Meyer SF, Stoll G, Wagner DD and Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2011 (Epub ahead of print).

  77. Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113:3600–3.

    Article  PubMed  CAS  Google Scholar 

  78. De Meyer SF, Schwarz T, Deckmyn H, Denis CV, Nieswandt B, Stoll G, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice—brief report. Arterioscler Thromb Vasc Biol. 2010;30:1949–51.

    Article  PubMed  Google Scholar 

  79. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593–603.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. INSERM U770, 80 rue du General Leclerc, 94276, Le Kremlin-Bicêtre, France

    Cécile V. Denis & Peter J. Lenting

  2. UMR_S 770, Univ Paris Sud, 94276, Le Kremlin-Bicêtre, France

    Cécile V. Denis & Peter J. Lenting

Authors
  1. Cécile V. Denis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Lenting
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cécile V. Denis.

About this article

Cite this article

Denis, C.V., Lenting, P.J. von Willebrand factor: at the crossroads of bleeding and thrombosis. Int J Hematol 95, 353–361 (2012). https://doi.org/10.1007/s12185-012-1041-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1041-x

Keywords

Search

Navigation